All News

RheumNow Podcast square

Is Cannabis Safe? (6.7.2024)

Jack Cush, MD

Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!

Read Article
PSA%20026.jpg

Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis

Jack Cush, MD

A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO. 

Read Article
RheumNow Podcast square

The Window of Opportunity (5.24.2024)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?

Read Article
Biomarker,genes

Biomarkers Predictive of a Deucravacitinib Response in Psoriatic Arthritis

Jack Cush, MD

A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.

Read Article
psor.elb_.jpg

Window of Opportunity in Psoriatic Arthritis

Jack Cush, MD

The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome. 

Read Article
podcast logo

"Don't You Know Who I am?" (5.17.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?

Read Article
Winthrop RNL

ICYMI: Five Takeaways in PsA/SpA at RNL 2024

Rachel Tate, DO

Continuing with the theme of clinical pearls, the PsA and SpA speakers also provided a wealth of information. Here are my five key takeaways and clinical pearls. 

Read Article
Study of 150 #PsA pts & Aortic stiffness (carotid-femoral pulse wave velocity (cfPWV) - cfPWV signif higher in PsA vs controls (p=0.034). , cfPWV assoc w/ Dz duration (r=0.3), systolic BP, GFR, RDW. cfPWV was superior to SCORE (16% vs 8.7%) at CV risk https://t.co/H6SbsIdXw0 https://t.co/Yt19QCk9TT

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/NMWtHB94Pi https://t.co/ok43pnagFg

Links:

Dr. John Cush RheumNow ( View Tweet)
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis A single center study demonstrates that biologic treatment of PsO significantly reduces the likelihood of PsA development; suggesting a role for more aggressive treatment of PsO. https://t.co/VHk2KEsP8d https://t.co/1r4zVAzrMw

Links:

Dr. John Cush RheumNow ( View Tweet)
Do you have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/qvVEUoNYi5 https://t.co/duw6jg5xpp

Links:

Dr. John Cush RheumNow ( View Tweet)
Biomarkers Predictive of a Deucravacitinib Response in PsA A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in PsA suggests specific biologic effects identified by biomarkers may predict clinical responses. https://t.co/zsZl7JQydn https://t.co/4mGBYB4qU4

Links:

Dr. John Cush RheumNow ( View Tweet)
384 Psoriasis pts followed mean 33 mos, 56 (14.6%) developed new-onset PsA. 311/384 (81%) had arthralgia (subclinical PsA) & 9.4% got PsA within 12 mos (23% by 36%). Subclinical more likely than PSO to get PsA (OR 11.7) https://t.co/9t41cjROwW https://t.co/9AelBwoRzs

Links:

Dr. John Cush RheumNow ( View Tweet)
Window of Opportunity in Psoriatic Arthritis The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome. https://t.co/eUL1wzrXVt https://t.co/XSETW2zpGs

Links:

Dr. John Cush RheumNow ( View Tweet)
NON-treatment of 18,318 VA pts (RA, SpA, PsA) = 41% not Rx DMARDs w/in 12 mos of Dx. Signif higher odds if Black (HR 1.13), Hispanic (1.14), Charlson Comorbidity ≥2 (1.15), opiate use (1.09). DMARD use ^ if married, w/ erosions, female MD, Rheum Dx https://t.co/TaYC27oIOz https://t.co/qjfAGI5L5g

Links:

Dr. John Cush RheumNow ( View Tweet)
MarketScan Claims & Medicaid study of incident AS, PsA, or RA (2010–2017) that Opioid use was highly prevalent in AS (36%), PsA (30%), & RA (44%) in the year prior to Dx & during the 1st Yr. Is this PCP or Rheumatologist mismanagement? https://t.co/YsCOLZUCfS https://t.co/b33uNg6Ucx

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! We’ll be covering #EULAR24! https://t.co/HGjP2SFyOp
Dr. John Cush RheumNow ( View Tweet)
2023 Top 3 paper from JAMA Derm - 122 plaque psoriasis pts (mild-mod w/ PASI=3.1) & low vit D levels (~14.9), Rx w/ PBO vs vit D 20 000 IU/wk x 4 mos during winter; no signif vit D Rx benefit for PASI, MD global, DLQI or 25-OH levels(< than expected) https://t.co/8W5abvydY6 https://t.co/rKJjkiHwC6

Links:

Dr. John Cush RheumNow ( View Tweet)
French insurance claims study of 12071 #PsA pts on biologics (2015-2021) found total of 367 serious infections (3%; IR 1.7/100PY). SIR risk significantly lower for new users of etanercept (wHR 0.72) & ustekinumab (wHR 0.57) (vs ADA new users https://t.co/CutqoxA05e https://t.co/OUCUbrKnFF

Links:

Dr. John Cush RheumNow ( View Tweet)
In biologic-naïve active PsA pts Rx w/ guselkumab & achieving enthesitis (ER) or dactylitis resolution (DR), had better PRO outcomes. GUS - ER or DR was assoc w/ minimal pain (p < 0.001), normalized HAQ-DI (p < 0.001), , better FACIT-Fatigue responses https://t.co/HymI7CBfXh https://t.co/dYk9qXdVpt

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×